JP2024503277A - 活性化抗原担体の製剤 - Google Patents

活性化抗原担体の製剤 Download PDF

Info

Publication number
JP2024503277A
JP2024503277A JP2023539809A JP2023539809A JP2024503277A JP 2024503277 A JP2024503277 A JP 2024503277A JP 2023539809 A JP2023539809 A JP 2023539809A JP 2023539809 A JP2023539809 A JP 2023539809A JP 2024503277 A JP2024503277 A JP 2024503277A
Authority
JP
Japan
Prior art keywords
aac
formulation
antigen
adjuvant
aacs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023539809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503277A5 (https=
JPWO2022147442A5 (https=
Inventor
ハワード バーンスタイン，
デフネ ヤラル，
カタリナ ブラゴヴィッチ，
アムリタ ラマクリシュナン，
マイサム ダドガー，
ルイーズ クリア，
ジェイソン マリー，
タレク アブデルジャワド，
クレア ページ，
Original Assignee
スクイーズ バイオテクノロジーズ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スクイーズ バイオテクノロジーズ カンパニー filed Critical スクイーズ バイオテクノロジーズ カンパニー
Publication of JP2024503277A publication Critical patent/JP2024503277A/ja
Publication of JP2024503277A5 publication Critical patent/JP2024503277A5/ja
Publication of JPWO2022147442A5 publication Critical patent/JPWO2022147442A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023539809A 2020-12-29 2021-12-28 活性化抗原担体の製剤 Pending JP2024503277A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063131457P 2020-12-29 2020-12-29
US63/131,457 2020-12-29
PCT/US2021/073142 WO2022147442A1 (en) 2020-12-29 2021-12-28 Formulations of activating antigen carriers

Publications (3)

Publication Number Publication Date
JP2024503277A true JP2024503277A (ja) 2024-01-25
JP2024503277A5 JP2024503277A5 (https=) 2024-12-25
JPWO2022147442A5 JPWO2022147442A5 (https=) 2024-12-25

Family

ID=80123528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023539809A Pending JP2024503277A (ja) 2020-12-29 2021-12-28 活性化抗原担体の製剤

Country Status (6)

Country Link
US (1) US20220233676A1 (https=)
EP (1) EP4271407A1 (https=)
JP (1) JP2024503277A (https=)
CN (1) CN116847880A (https=)
CA (1) CA3203709A1 (https=)
WO (1) WO2022147442A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154696A1 (en) * 2019-01-25 2020-07-30 Sqz Biotechnologies Company Anucleate cell-derived vaccines
WO2020176789A1 (en) * 2019-02-28 2020-09-03 Sqz Biotechnologies Company Delivery of biomolecules to pbmcs to modify an immune response

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
WO2005072523A2 (en) * 2004-02-02 2005-08-11 I.M.T. Interface Multigrad Technology Ltd. Biological material and methods and solutions for preservation thereof
ES2482192T3 (es) * 2007-05-31 2014-08-01 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Vacunación intradérmica del péptido de HPV
CN107058101B (zh) 2011-10-17 2021-06-01 麻省理工学院 细胞内传递
EP3033184B1 (en) 2013-08-16 2021-03-31 Massachusetts Institute of Technology Selective delivery of material to cells
ES2865825T3 (es) * 2014-04-01 2021-10-18 Rubius Therapeutics Inc Procedimientos y composiciones para inmunomodulación
JP7523203B2 (ja) * 2014-10-31 2024-07-26 マサチューセッツ インスティテュート オブ テクノロジー 生体分子の免疫細胞への送達
SG10201912910PA (en) 2015-07-09 2020-02-27 Massachusetts Inst Technology Delivery of materials to anucleate cells
ES2930017T3 (es) 2015-09-04 2022-12-05 Sqz Biotechnologies Co Suministro intracelular de biomoléculas mediado por una superficie con poros
CN108779475A (zh) * 2016-01-12 2018-11-09 Sqz生物技术公司 复合物的细胞内递送
JP7602702B2 (ja) 2016-05-03 2024-12-19 ステムセル テクノロジーズ カナダ インコーポレーテッド 寛容性を誘導するための生体分子の細胞内送達
KR102490952B1 (ko) 2016-05-03 2023-01-19 에스큐지 바이오테크놀로지스 컴퍼니 관용을 유도하는 생체분자의 세포내 전달
EP3765068A2 (en) 2018-03-12 2021-01-20 SQZ Biotechnologies Company Intracellular delivery of biomolecules to modify immune response
US12599656B2 (en) 2018-03-12 2026-04-14 Stemcell Technologies Canada Inc. Methods for treating HPV-associated diseases
KR20210070338A (ko) 2018-10-04 2021-06-14 에스큐지 바이오테크놀로지스 컴퍼니 항원 제시 세포 기능을 증진시키기 위한 생체분자의 세포내 전달
EP4188425B1 (en) * 2020-07-29 2025-05-14 Stemcell Technologies Canada Inc. Methods to stimulate immune responses to mutant ras using anucleate cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154696A1 (en) * 2019-01-25 2020-07-30 Sqz Biotechnologies Company Anucleate cell-derived vaccines
WO2020176789A1 (en) * 2019-02-28 2020-09-03 Sqz Biotechnologies Company Delivery of biomolecules to pbmcs to modify an immune response

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Product Information, Catalog Numbers C3124, C2999, and C2874", SIGMA-ALDRICH, JPN6026012570, November 2010 (2010-11-01), ISSN: 0005831041 *
THE JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. Vol.8, Suppl.3, A98-A99, 165, JPN6025039777, 10 December 2020 (2020-12-10), ISSN: 0005831040 *

Also Published As

Publication number Publication date
US20220233676A1 (en) 2022-07-28
CN116847880A (zh) 2023-10-03
EP4271407A1 (en) 2023-11-08
WO2022147442A1 (en) 2022-07-07
CA3203709A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
KR102484433B1 (ko) T 세포 제조 조성물 및 방법
KR102756321B1 (ko) T 세포 제조 조성물 및 방법
JP4610847B2 (ja) すぐ使用できる、抗原負荷また非負荷の凍結保存された成熟成樹状細胞の調製方法
JP7604000B2 (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
HK1248523A1 (zh) 用电穿孔向细胞负载抗原
Erdmann et al. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection
US20040214333A1 (en) Loading of cells with antigens by electroporation
JP2018531022A6 (ja) 改変ヒト初代血液樹状細胞株を生成するための方法
KR102919756B1 (ko) 치료용 수지상 세포의 시험관내 분화 및 성숙 방법
US12150982B2 (en) Formulations of PBMCs
JP2024538129A (ja) Ｔ細胞製造組成物および方法
JP2024503277A (ja) 活性化抗原担体の製剤
WO2021213446A1 (zh) 生物样品低温储存
EP3943932A1 (en) Method for providing immune cells
WO2025212998A1 (en) Treatment of mgmtp unmethylated glioblastoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251223

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260401